Hubei Vanz Pharm Co.,Ltd
Diamond Supplier Enterprise Certification
- Diamond
Supplier - 6th
years
Diamond Supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: 86-27-84492310
Tel: 008618986076206
Tel: +86 27 84492310
Tel: WhatsApp +8615927784577
Tel: +8618071739296
Mobile: +8615207100586
Tel: 86-27-84492310
Fax: 86-27-84402310
URL: http://www.vanzpharm.com/en/index.html
Province/state: Hubei
City: JIAYU
Street: FANHU INDUSTRY PARK
MaxCard:
Ms.Bella Li Ms.Chelsea GaoCAS NO.459789-99-2
cas 459789-99-2 99 % purity Obeticholic Acid powder
Product Name: Obeticholic Acid
CAS: 459789-99-2
MF: C26H44O4
MW: 420.63
EINECS: 810-245-2
cas 459789-99-2 99 % purity Obeticholic Acid powder
Product Name: Obeticholic Acid
CAS: 459789-99-2
MF: C26H44O4
MW: 420.63
EINECS: 810-245-2
Obeticholic acid is a potent and selective farnesoid X receptor agonist that promotes the flow of bile in the liver. The drug was approved by the USFDA for the treatment of the rare chronic liver disease primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA or as a single agent therapy in adults unable to tolerate UDCA. Obeticholic acid was discovered at the Università de Perugia and developed by Intercept Pharmaceuticals. Obeticholic acid has also been granted orphan drug designation for the treatment of primary sclerosing cholangitis and primary biliary cirrhosis and has received breakthrough therapy designation for the treatment of patients with nonalcohol steatohepatitis (NASH) with liver fibrosis.
Obeticholic acid is a semi-synthetic bile acid analogue and acts as a farnesoid-X receptor (FXR) agonist. It is used for the treatment of primary biliary cholangitis. It is also under investigation for the treatment of other liver diseases,primary biliary cirrhosis, bile acid diarrhea and related disorders. Study has shown that it also has potential for treating nonalcoholicsteatohepatitis (NASH), and portal hypertension. Obeticholic acid takes effect through acting s the agonist of the farnesoid X receptor (FXR), which is the regulator of bile and cholesterol metabolism in the liver.